Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PHD finger protein 12 (PHF12)
- Target
- PHF12
- Molecular classification
- Zinc finger protein, Chromatin regulator, Transcription corepressor, Epigenome reader, Histone modification "reader" domain
01
Overview
PHD finger protein 12 is a protein-coding gene product characterized by a PHD (plant homeodomain) zinc finger domain. It acts as a transcriptional repressor within SIN3B-type and other chromatin-modifying complexes, stabilizing protein-protein interaction and reading methylation marks on histone H3, notably H3K27ac. PHF12 plays a central role in the negative regulation of gene expression by modulating chromatin state and counteracting the activity of histone acetyltransferases. It operates mainly in the nucleoplasm, recruiting chromatin remodeling complexes and influencing RNA polymerase II transcriptional activity[1][3][5]. Dysregulation of PHF12 or related chromatin remodelers is associated with disease states driven by aberrant gene expression and epigenetic changes.
- Other names
- PHF12PHD finger protein 12PHF12_HUMAN
02
Mechanism of action
Drugs targeting similar proteins generally modulate chromatin state by inhibiting or promoting histone acetylation/deacetylation, but no PHF12-targeted agents are listed
03
Biological functions
Transcriptional repressionNegative regulation of DNA-templated transcriptionChromatin remodelingRecruitment of multi-protein complexesRegulation of gene expressionHistone recognition and binding (especially to methylated H3 tails)Protein-protein interaction
04
Disease associations
Peroneal nerve paralysisHeel spurPotential roles in cancer and other diseases driven by epigenetic dysregulation (based on family function)
05
Safety considerations
Not specifically described; however, targeting chromatin regulators may affect cell proliferation and viability, posing off-target and epigenetic risks if developed as a therapeutic target
06
Interacting drugs
None currently known; no approved drugs directly target PHF12 as of current literature
07
Biomarkers
None established for patient selection or monitoring in clinical settings
Beyond the preview
Go deeper on PHD finger protein 12 (PHF12).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PHD finger protein 12 (PHF12).